Ishrak has led the company for nearly nine years and will retire at the end of the fiscal year in late April turning over the reins to his deputy Geoff Martha who, like Ishrak, came to Medtronic from GE Healthcare.
Medtronic's new deep brain stimulation device, Percept, reads brain signals to better optimize treatment. Traditionally, physicians adjust DBS signals based on a patient’s diary entries, which can be imprecise.
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
Venclose has received $27 million in Series C funding to expand market share for it venous reflux therapy. This RF ablation device is designed to simplify treatment and reduce procedure times.
Don't mistake Stryker's latest $500 million deal in the spine market as a simple tuck-in acquisition, says one analyst while another says it could help Stryker give Medtronic a run for its money.
After diabetes, Medtronic is looking to leverage AI through a distribution agreement with Viz.ai, which uses the technology to streamline stroke care.
The San Diego-based company has is in the midst of one of the most precipitous turnarounds in the medical device industry and is well positioned to grow alongside the expanding insulin pump market.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
Medtronic announced data at the annual meeting of the American Diabetes Association on Monday that shows that people using its AI-powered Sugar.IQ diabetes assistant have better control of their blood glucose levels.
On the day that an FDA official exhorts industry to develop interoperable diabetes devices, Medtronic announces that it is teaming up with a nonprofit group to do just that.
MedCity News caught up with Omron Healthcare CEO Ranndy Kellogg at the the AdvaMed Digital MedTech Conference in San Francisco to speak about the company's new products, emerging business lines and how collaboration with other companies have driven recent innovation.
Dexcom's executives lay out the land in terms of competition in the standalone continuous glucose monitoring market while Medtronic CEO responds.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
While the development of renal denervation technologies stalled after a failed Medtronic study in 2014, recent positive research results have led to increasing interest - and investment - in the space.
Medtronic said the company will be rolled into its Diabetes Group to improve its diabetes management capabilities by adding Nutrino's comprehensive food database, food analysis system and nutrition-science expertise.
An expensive failed acquisition, sales force flux, off-label use of a controversial biologics product, a DOJ investigation and nimble competitors chipping away has hobbled Medtronic's spine business. The purchase of Mazor Robotics aims to be a major reset.
In less than a decade, the chief patient officer - and similar roles with different titles - has become a key part of the healthcare industry executive team.
Medtronic had previously betted on higher adoption of its insulin pumps tethering the use of continuous glucose monitors to those pumps but has recently returned to the standalone CGM market with the launch of its Guardian Connect device in the U.S. Should Dexcom and Abbott worry?